96 studies found for:    "childhood myocerebrohepatopathy spectrum" OR "Mitochondrial Diseases"
Show Display Options
Rank Status Study
21 Completed Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)
Condition: MELAS Syndrome
Intervention: Biological: Intramuscular seasonal trivalent inactivated influenza vaccine
22 Completed Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder
Condition: Chronic Fatigue Syndrome
Intervention: Drug: Nutraceuticals
23 Recruiting Natural History Study - Mitochondrial Disease
Condition: Mitochondrial DNA Mutation
Intervention:
24 Recruiting Phase 2 Study of EPI-743 in Children With Pearson Syndrome
Condition: Pearson Syndrome
Intervention: Drug: EPI-743
25 Unknown  Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome
Condition: MELAS Syndrome
Intervention: Drug: Dichloroacetate
26 Active, not recruiting Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome
Condition: Leigh Syndrome
Interventions: Drug: Placebo;   Drug: EPI-743 15 mg/kg;   Drug: EPI-743 5 mg/kg
27 Completed Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects
Conditions: Carnitine Palmitoyltransferase II Deficiency;   Very Long Chain Acyl Coa Dehydrogenase Deficiency
Interventions: Drug: Bezafibrate;   Other: Placebo
28 Completed High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders
Conditions: Very Long-chain Acyl-CoA Dehydrogenase Deficiency;   Trifunctional Protein Deficiency;   Carnitine Palmitoyltransferase 2 Deficiency;   Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
Intervention: Behavioral: Diet counseling
29 Recruiting Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Conditions: Insulin Sensitivity;   Multiple Mitochondrial Dysfunctions Syndrome
Interventions: Drug: Dapagliflozin;   Drug: Placebo
30 Unknown  Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment
Conditions: Dyskeratosis Congenita;   Fanconi Anemia;   Myelodysplastic Syndromes;   Nonmalignant Neoplasm;   Pearson Marrow-pancreas Syndrome;   Shwachman-diamond Syndrome
Interventions: Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunologic technique;   Procedure: biopsy
31 Completed Abdominal Adiposity and Muscle Mitochondrial Functions
Condition: Mitochondrial Respiratory Chain Deficiencies
Intervention:
32 Active, not recruiting EPI-743 for Metabolism or Mitochondrial Disorders
Conditions: Metabolic Disease;   Neurology;   Myoptahy
Intervention: Drug: EPI-743
33 Unknown  Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder
Condition: Chronic Fatigue Syndrome
Interventions: Drug: Nutraceutical supplements;   Drug: Placebo
34 Completed Mitochondria and Metabolic Syndrome in a Southern California Chinese Cohort
Conditions: Metabolic Syndrome;   Type 2 Diabetes Mellitus
Intervention: Device: Diffuse Optical Spectroscopy
35 Terminated The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
Conditions: Argininosuccinic Aciduria;   Carbamoyl-Phosphate Synthase I Deficiency;   Citrullinemia;   Ornithine Carbamoyltransferase Deficiency;   Hyperargininemia;   N-Acetylglutamate Synthase Deficiency
Intervention:
36 Completed L-arginine Therapy on Endothelium-dependent Vasodilation & Mitochondrial Metabolism in MELAS Syndrome
Condition: MELAS Syndrome
Intervention: Drug: L-Arginine
37 Completed Transitional Life Events in Patients With Friedreich's Ataxia: Implications for Genetic Counseling
Condition: Friedreich Ataxia
Intervention:
38 Recruiting Short-term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Conditions: Propionic Acidemia (PA);   Methylmalonic Acidemia (MMA);   Late-onset CPS1 Deficiency (CPSD);   Late-onset Ornithine Transcarbamylase Deficiency (OTCD)
Interventions: Drug: Carbaglu;   Drug: Placebo;   Drug: Standard Care Treatment
39 Completed
Has Results
Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
Condition: Trifunctional Protein Deficiency
Intervention:
40 Available Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders;   Pyruvate Carboxylase Deficiency, Type B;   Acyl-coA Dehydrogenase, Type 9
Intervention: Drug: triheptanoin

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years